Comparative Pharmacology
Head-to-head clinical analysis: VASCORAY versus VISIPAQUE 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VASCORAY versus VISIPAQUE 320.
VASCORAY vs VISIPAQUE 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
Intravascular administration: Adult dose is 50-150 mL (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Primarily renal (90% unchanged), with 10% biliary/fecal.
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent